Maurizio Zangari, MD

Research Program: Cancer Therapeutics Faculty Rank: Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Internal Med Myeloma Clinical

Cancer Research Interest

• Disease Site Focus: Multiple Myeloma, Musculoskeletal
• Research Focus Area: Treatment, Detection, Carcinogenesis, Diagnosis/ Prognosis
• Type of Research: Clinical

Contact Information

• Email Address: MZANGARI@UAMS.EDU
• Profiles Research Networking Software: View Profile

Recent Publications

• Pandey T, Mohan Lal B, Alrawabdeh J, [et al., including Zangari M]. Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma. Blood cancer journal. 2026 16(1):4. PMID: 41495017.
• Ling W, Zangari M, Van Rhee F, [et al.]. Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice. Haematologica. 2025 110(11):2740-2751. PMID: 40501401.
• Mery DE, Tricot G, Al Hadidi S, [et al., including Zangari M]. Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans. Blood cancer journal. 2025 15(1):164. PMID: 41102157.
• Shrestha A, Thanendrarajan S, Bag A, [et al., including Zangari M]. The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia. Blood advances. 2025 9(19):4806-4809. PMID: 40674710.
• Schinke CD, Rasche L, Ashby TC, [et al., including Zangari M]. Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging. Blood advances. 2025 9(17):4368-4377. PMID: 40590883.
• Al-Sawajneh S, Desikan SP, Gokden N, [et al., including Zangari M]. Heavy Chain Cast Nephropathy in a Gamma Heavy Chain Disease: RESPONSE to High-Dose Therapy Melphalan and Daratumumab. Clinical lymphoma, myeloma & leukemia. 2025 25(9):e704-e708. PMID: 40634181.
• Sabol HM, Anloague A, Kaur J, [et al., including Zangari M]. Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition. Experimental hematology & oncology. 2025 14(1):108. PMID: 40847323.
• Al Hadidi S, Ababneh OE, Schinke CD, [et al., including Zangari M]. Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials. JAMA oncology. 2025 11(8):910-915. PMID: 40471585. PMCID: PMC12142471.
• Mohan Lal B, Pandey T, Alzubi M, [et al., including Zangari M]. Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience. Bone marrow transplantation. 2025 60(7):1057-1059. PMID: 40246944.
• Sun F, Cheng Y, Ma C, [et al., including Zangari M]. Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma. Cancer biomarkers : section A of Disease markers. 2025 42(6):18758592251344936. PMID: 40485257.
• Mohan Lal B, Alzubi M, Alrawabdeh J, [et al., including Zangari M]. Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma. Blood advances. 2025 9(9):2155-2158. PMID: 39938011. PMCID: PMC12051553.
• Mohan M, Szabo A, Cheruvalath H, [et al., including Zangari M]. Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood cancer journal. 2025 15(1):74. PMID: 40268898. PMCID: PMC12018942.
• Al Hadidi S, Ababneh O, Schinke C, [et al., including Zangari M]. Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma. Blood advances. 2025 9(4):950-953. PMID: 39786380. PMCID: PMC11934280.
• Cheng Y, Sun F, Alapat DV, [et al., including Zangari M]. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood cancer journal. 2024 14(1):194. PMID: 39505839. PMCID: PMC11541562.
• Al Hadidi S, Ababneh O, Schinke C, [et al., including Zangari M]. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. American journal of hematology. 2024 99(11):2222-2224. PMID: 39109821.
• Akhtar OS, Szabo A, Bhatlapenumarthi V, [et al., including Zangari M]. Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies. British journal of haematology. 2024 205(5):1830-1834. PMID: 39192546.
• Naqvi S, Shrestha A, Alzubi M, [et al., including Zangari M]. Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab. EJHaem. 2024 5(4):789-792. PMID: 39157593. PMCID: PMC11327703.
• Shrestha A, Alzubi M, Alrawabdeh J, [et al., including Zangari M]. B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma. EJHaem. 2024 5(3):554-559. PMID: 38895072. PMCID: PMC11182413.
• Mohan M, Szabo A, Patwari A, [et al., including Zangari M]. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone marrow transplantation. 2024 59(5):647-652. PMID: 38361116.
• Guo W, Strouse C, Mery D, [et al., including Zangari M]. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers. 2024 16(6). PMID: 38539451. PMCID: PMC10969019.
• Mohan M, Monge J, Shah N, [et al., including Zangari M]. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood cancer journal. 2024 14(1):35. PMID: 38443345. PMCID: PMC10914756.
• Hammons L, Szabo A, Janardan A, [et al., including Zangari M]. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024 109(3):906-914. PMID: 37646658. PMCID: PMC10905074.
• Guo W, Zhan Y, Mery D, [et al., including Zangari M]. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood cancer journal. 2024 14(1):30. PMID: 38355688. PMCID: PMC10866867.
• Al Hadidi S, Ababneh O, Schinke C, [et al., including Zangari M]. Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood advances. 2024 8(3):703-707. PMID: 38052037. PMCID: PMC10845028.
• Sun F, Cheng Y, Wanchai V, [et al., including Zangari M]. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nature communications. 2024 15(1):615. PMID: 38242888. PMCID: PMC10798961.
• Sun F, Cheng Y, Chen JR, [et al., including Zangari M]. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. The Journal of clinical investigation. 2024 134(1). PMID: 37883186. PMCID: PMC10760955.
• Patel TH, Bachu R, Shrivastava T, [et al., including Zangari M]. Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Clinical hematology international. 2024 6(3):54-60. PMID: 39345654. PMCID: PMC11428156.
• Guo W, Zhan A, Mery DE, [et al., including Zangari M]. Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS. Blood advances. 2023 7(21):6676-6684. PMID: 37756524. PMCID: PMC10637884.
• Cheng Y, Sun F, Alapat DV, [et al., including Zangari M]. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine. 2023 4(10):101214. PMID: 37794587. PMCID: PMC10591052.
• Mehdi SJ, Ghatak K, Ling W, [et al., including Zangari M]. Growth and dormancy control of myeloma cells by mesenchymal stem cells. Leukemia research. 2023 133:107355. PMID: 37499483.
• Ling W, Johnson SK, Mehdi SJ, [et al., including Zangari M]. EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression. Cancers. 2023 15(18). PMID: 37760488. PMCID: PMC10526862.
• Fahmawi S, Schinke C, Thanendrarajan S, [et al., including Zangari M]. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines. Journal of cancer policy. 2023 37:100433. PMID: 37468042.
• John L, Poos AM, Brobeil A, [et al., including Zangari M]. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nature communications. 2023 14(1):5011. PMID: 37591845. PMCID: PMC10435504.
• Mohan M, Gong Z, Ashby TC, [et al., including Zangari M]. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023 129(16):2491-2498. PMID: 37282609.
• Mazahreh F, Mazahreh L, Schinke C, [et al., including Zangari M]. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood advances. 2023 7(13):3069-3074. PMID: 36857755. PMCID: PMC10331406.
• Sun F, Cheng Y, Ying J, [et al., including Zangari M]. A gene signature can predict risk of MGUS progressing to multiple myeloma. Journal of hematology & oncology. 2023 16(1):70. PMID: 37386588. PMCID: PMC10308756.
• Al Hadidi S, Dongarwar D, Schinke C, [et al., including Zangari M]. Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. Clinical hematology international. 2023 5(2-3):57-60. PMID: 36737587. PMCID: PMC10241736.
• Abu Za'nouneh FJ, Ababneh O, Schinke C, [et al., including Zangari M]. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023 4(2):454-458. PMID: 37206288. PMCID: PMC10188470.
• Al Hadidi S, Szabo A, Esselmann J, [et al., including Zangari M]. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone marrow transplantation. 2023 58(4):443-445. PMID: 36550200.
• Mohan M, Rein LE, Thalambedu N, [et al., including Zangari M]. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. American journal of hematology. 2022 97(12):E451-E453. PMID: 36097868.
• Schinke C, Poos AM, Bauer MA, [et al., including Zangari M]. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood advances. 2022 6(22):5873-5883. PMID: 35977111. PMCID: PMC9647426.
• Gai D, Chen JR, Stewart JP, [et al., including Zangari M]. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. The Journal of clinical investigation. 2022 132(18). PMID: 35881476. PMCID: PMC9479617.
• Al Hadidi S, Dongarwar D, Salihu H, [et al., including Zangari M]. Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Clinical hematology international. 2022 4(3):117-120. PMID: 36131130. PMCID: PMC9492819.
• Rasche L, Schinke C, Maura F, [et al., including Zangari M]. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nature communications. 2022 13(1):4517. PMID: 35922426. PMCID: PMC9349320.
• Alqazaqi R, Schinke C, Thanendrarajan S, [et al., including Zangari M]. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA network open. 2022 5(8):e2228877. PMID: 36018590. PMCID: PMC9419017.
• Mikulasova A, Kent D, Trevisan-Herraz M, [et al., including Zangari M]. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome research. 2022 32(7):1343-1354. PMID: 34933939. PMCID: PMC9341503.
• Abushukair H, Syaj S, Ababneh O, [et al., including Zangari M]. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis. American journal of hematology. 2022 97(7):942-950. PMID: 35358350.
• Mohan M, Becnel MR, Shah UA, [et al., including Zangari M]. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. American journal of hematology. 2022 97(7):E276-E280. PMID: 35472167. PMCID: PMC10476149.
• Mohan M, Gundarlapalli S, Szabo A, [et al., including Zangari M]. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American journal of hematology. 2022 97(6):E195-E198. PMID: 35285981.
• Al Hadidi S, Zangari M, van Rhee F. Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions. JAMA oncology. 2022 8(6):823-824. PMID: 35482363.
• Al Hadidi S, Schinke C, Thanendrarajan S, [et al., including Zangari M]. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA network open. 2022 5(4):e228161. PMID: 35442451. PMCID: PMC9021907.
• Larsen K, Spencer H, Mohan M, [et al., including Zangari M]. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of clinical medicine. 2022 11(6). PMID: 35329966. PMCID: PMC8955129.
• Mohan M, Kendrick S, Szabo A, [et al., including Zangari M]. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood advances. 2022 6(3):808-817. PMID: 34807986. PMCID: PMC8945288.
• Boyle EM, Rosenthal A, Ghamlouch H, [et al., including Zangari M]. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2022 36(2):591-595. PMID: 34365473.
• Baker D, Bimali M, Carrillo L, [et al., including Zangari M]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 106(12):3215-3218. PMID: 34847659. PMCID: PMC8634177.
• Boyle EM, Rosenthal A, Wang Y, [et al., including Zangari M]. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British journal of haematology. 2021 195(2):283-286. PMID: 34244996.
• Mohan M, Szabo A, Yarlagadda N, [et al., including Zangari M]. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. American journal of hematology. 2021 96(9):E341-E344. PMID: 34050985.
• Yarlagadda L, Boerma M, Gundarlapalli S, [et al., including Zangari M]. Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers. 2021 13(16). PMID: 34439174. PMCID: PMC8392190.
• Schinke CD, Boerma M, Bird JT, [et al., including Zangari M]. PHF19 inhibition as a therapeutic target in multiple myeloma. Current research in translational medicine. 2021 69(3):103290. PMID: 33894670. PMCID: PMC8316274.